



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hsuan-Yin Lan-Hargest et al. Art Unit : 1617  
 Serial No. : 09/812,945 Examiner : M. Bahar  
 Filed : March 27, 2001  
 Title : HISTONE DEACETYLASE INHIBITORS

**BOX AF**

Commissioner for Patents  
 Washington, D.C. 20231

# 8/1 AF  
 MP600  
 6/23/02  
 RECEIVED  
 JUL 26 2002  
 TECH CENTER 1600/2900

**RESPONSE**

In response to the action mailed April 23, 2002 ("Office Action"), please amend the application as follows:

In the claims:

Please cancel claims 54-66 without prejudice.

**REMARKS**

Claims 54-66 have been cancelled without prejudice. Claims 1-53 are pending. Claims 1 and 47 are independent.

Applicants thank the Examiner for withdrawing the rejection under 35 U.S.C. §§ 101/112, first paragraph. See page 2 of the Office Action.

The Examiner indicated that Applicants' request to rejoin Group I and Group II has been denied because "the invention [sic] in Groups I and II are distinct since they have different functions, i.e., inhibition of histone deacetylase vs. treatment of cancer." See page 2 of the Office Action. Applicants continue to disagree. While the Examiner asserts that these are "distinct", Applicants reiterate that both Group I and Group II are drawn to methods of inhibiting histone deacetylase in cells. Both groups are classified in class 514, subclass 575+. Applicants believe the scope of the search required to examine Group I and Group II covers the same material. Applicants respectfully request reconsideration of this aspect of the restriction.

Applicants also respectfully request that claims 21 and 22 be grouped with the claims 1, 2, 4-7, 10, 12, 17-18 and 40-46.

**Rejection under 35 U.S.C. § 112, first paragraph**

Claims 1, 2, 4-7, 10, 12, 17-18 and 40-46 have been rejected under 35 U.S.C. § 112, first paragraph,